Association Between Serum Levels of Carotenoids and Serum Asymmetric Dimethylarginine Levels in Japanese Subjects

Rika Watarai¹, Koji Suzuki¹,², Naohiro Ichino³, Keisuke Osakabe³, Keiko Sugimoto³, Hiroya Yamada⁴, Takeshi Hamajima¹, Nobuyuki Hamajima⁵, and Takashi Inoue¹,²

¹Clinical Laboratory Medicine, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan
²Department of Public Health, Fujita Health University School of Health Sciences, Toyoake, Aichi, Japan
³Department of Clinical Physiology, Fujita Health University School of Health Sciences, Toyoake, Aichi, Japan
⁴Department of Hygiene, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
⁵Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

Received September 18, 2013; accepted January 8, 2014; released online April 12, 2014

ABSTRACT

Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelium nitric oxide synthase (NOS). ADMA binds to a substrate-binding site of NOS and then inhibits nitric oxide production from vascular endothelial cells. Elevated ADMA levels are a risk factor for cardiovascular disease. Recently, it was reported that plasma ADMA levels were negatively correlated with vegetable and fruit consumption. The purpose of this study was to examine the association between serum levels of carotenoids and serum ADMA levels in Japanese subjects.

Methods: We conducted a cross-sectional study of 470 subjects (203 men and 267 women) who attended a health examination in August 2011. Serum levels of several carotenoids were separately measured by high-performance liquid chromatography. Serum ADMA levels were determined by using an enzyme-linked immunosorbent assay kit.

Results: In women, the multivariate-adjusted odds ratios (ORs) of elevated serum ADMA levels were significantly decreased in the highest tertile for β-cryptoxanthin (OR 0.47, 95% CI 0.23–0.95), α-carotene (OR 0.39, 95% CI 0.18–0.79), and β-carotene (OR 0.36, 95% CI 0.17–0.73) compared to the lowest tertile. In men, significantly decreased ORs were observed in the highest tertiles of serum zeaxanthin/lutein (OR 0.23, 95% CI 0.06–0.69) and α-carotene (OR 0.26, 95% CI 0.07–0.82), and in the middle and the highest tertiles of serum β-carotene (OR 0.27, 95% CI 0.09–0.74 and OR 0.20, 95% CI 0.03–0.88, respectively) when the tertile cutoff points of women were extrapolated to men.

Conclusions: Higher serum levels of carotenoids, such as α-carotene and β-carotene, may help to prevent elevated serum ADMA levels in Japanese subjects.

Key words: asymmetric dimethylarginine; carotenoids; cross-sectional study

INTRODUCTION

Nitric oxide (NO) is synthesized from L-arginine by endothelium NO synthase (eNOS) in the vascular endothelium. Endothelium-derived NO is involved in anti-atherosclerotic biological activities, including vasodilation, leukocyte adhesion restraint, inhibition of vascular smooth muscle cell proliferation, and platelet aggregation inhibitory action. Dysfunction of the endothelial L-arginine/NO pathway is associated with hypertension, coronary heart disease, and diabetes. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of eNOS that competitively inhibits L-arginine oxidation. ADMA is combined in a substrate-binding site of NOS, but ADMA is not decomposed into NO. As a result, ADMA inhibits the NO production of the vascular endothelium. ADMA is a risk factor for endothelial dysfunction. Circulating plasma levels of ADMA are increased in patients with renal failure, hypertension, hyperlipidemia, type 2 diabetes, and coronary artery disease. ADMA formation occurs during the hydrolysis of methylated proteins and is catalyzed by protein arginine deiminase.

Address for correspondence. Koji Suzuki, Ph.D., Department of Public Health, Fujita Health University School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan (e-mail: ksuzuki@fujita-hu.ac.jp).
methyltransferases. ADMA is secreted into body fluids and excreted into the urine. Intracellular ADMA is hydrolyzed to dimethylamine and L-citrulline by dimethylarginine dimethylaminohydrolase (DDAH). The enzyme activity of DDAH is decreased by increased oxidative stress.

Plasma ADMA is negatively correlated with vegetable consumption in older healthy subjects. This association may play a role in the inverse association between vegetable consumption and cardiovascular disease (CVD) risk. However, the mechanisms underlying the association between vegetable consumption and ADMA are not completely understood.

Carotenoids are phytonutrients that have antioxidant properties. Circulating carotenoid concentrations are useful biomarkers of vegetable and fruit intake. Some epidemiological studies have reported that high circulating carotenoid levels were inversely related to the risk of CVD. We suggest that circulating carotenoids may play an important role in the inverse association of vegetable consumption with ADMA, because oxidative stress influences the metabolism of ADMA. To our knowledge, however, no epidemiological study has investigated the association between serum carotenoid levels and serum ADMA levels.

Here, we conducted the present study to determine the relationship between serum carotenoid levels and serum ADMA levels in Japanese subjects.

METHODS

This cross-sectional study is part of the ongoing Yakumo study, a population-based prospective study of lifestyle-related disease conducted in Yakumo-cho, Hokkaido, Japan. The study enrolled 526 subjects (210 men and 316 women), aged 40–91 years, who attended a health examination held in Yakumo-cho in August 2011. We excluded 12 subjects who did not provide informed consent for the present study and 44 subjects for whom adequate serum samples were not available to measure serum ADMA levels. The remaining 470 eligible subjects (203 men and 267 women) were included in the analysis. This study was approved by the Ethics Committee of Fujita Health University (approval number 11-101).

Fasting blood samples were taken during the health examination, and sera were immediately separated from blood samples by centrifugation. Sera were stored in a refrigerator for up to three days during the administration of health examinations and were transported to our laboratory at −80°C in our laboratory for up to six months. Serum levels of five carotenoids (zeaxanthin/lutein, β-cryptoxanthin, lycopene, α-carotene, β-carotene) were measured by high-performance liquid chromatography. We measured serum ADMA levels by using an enzyme-linked immunosorbent assay kit (ADMA Xpress ELISA kit; Immundiagnostik AG, Bensheim, Germany). The coefficients of variation (CVs) for the intra- and inter-assay of carotenoids were 4.5% to 9.2% and 9.2% to 20.0%, respectively. The intra- and inter-assay CVs for the measurement of ADMA were 5.8% (serum ADMA levels: 0.48 µmol/l) to 7.9% (0.19 µmol/l) and 7.6% (0.47 µmol/l) to 10.8% (0.19 µmol/l), respectively, values which were reported in the instruction manual as typical variation for the assay.

Serum creatinine levels were measured using an enzymatic method. Other biochemical analyses of sera were performed using an auto-analyzer (JCM-BM9130; Nihon Denshi Co., Ltd., Tokyo, Japan) at the laboratory of Yakumo General Hospital on the day of the health examination. We calculated the creatinine-based estimated glomerular filtration rate (eGFR) [eGFR = 194 × creatinine−1.094 × age−0.287 (× 0.739 in women)] as a marker for renal function. Blood pressure, body height, and weight were measured during the health examination. The body mass index (BMI) was calculated as body weight (kg) divided by height (m) squared. The value for glycated hemoglobin (HbA1c; %) was estimated as a National Glycohemoglobin Standardization Program (NGSP) equivalent value (%) calculated by the formula: HbA1c (NGSP) = 1.02 × HbA1c (JDS) + 0.25%, considering the relational expression of HbA1c (JDS) (%) measured by the previous Japanese standard substance and measurement methods and HbA1c (NGSP). Trained nurses obtained health information, including smoking habits (current smoker, former smoker, or never smoker), alcohol consumption (regular drinker, former drinker, or never drinker) and history of major illness (yes or no), using a questionnaire regarding health and daily lifestyle habits.

Statistical analyses were performed with the statistical software JMP ver. 10 (SAS Institute Inc., Cary, NC, USA). Since serum levels of carotenoids and ADMA were distributed logarithmically, we used log-transformed values for the analyses. The analysis of covariance and Tukey-Kramer HSD tests were conducted by sex to compare continuous parameters among quartiles of serum ADMA or tertiles of serum carotenoids. We analyzed sex differences in continuous parameters using Student’s t-test. The chi-square test was used to compare categorical variables. Serum levels of carotenoids and ADMA were represented as geometric means and 25th–75th percentile ranges. Other variables were represented as mean ± standard deviation (SD). Adjusted odds ratios (ORs) with 95% confidence intervals (CI) were estimated by multivariate logistic regression analysis. We divided the distribution of the serum carotenoid levels into tertiles and calculated the odds of elevated serum ADMA levels (greater than the 75th percentile) among tertiles of serum carotenoid levels using the lowest tertile as a reference. In logistic regression analysis, we included variables that might confound the association of serum carotenoid levels with serum ADMA levels, including age, smoking habits, drinking habits, BMI, eGFR, serum γ-glutamyl transpeptidase.
Association Between Serum Carotenoids and Asymmetric Dimethylarginine

RESULTS

Table 1 shows the characteristics of subjects stratified by sex and tertile of ADMA (<25th percentile, 25th–75th percentile, and ≥75th percentile). The mean age ± SD of study subjects was 66.5 ± 10.0 years for men and 65.6 ± 9.7 years for women. Serum ADMA levels were significantly higher in men than in women (P < 0.001). Serum levels of all carotenoids were significantly higher in women than in men (P < 0.001). Men had significantly higher serum levels of triglycerides and γ-GTP and significantly lower serum total cholesterol and HDL-cholesterol compared to women. Proportions of current smokers and current drinkers were significantly higher in men than in women. Serum γ-GTP activities decreased with increasing serum ADMA levels in men. In men, DBP was significantly lower in the middle group compared to that in the lowest quartile. The mean age was significantly higher in the middle group than in the lowest quartile in women.

Table 2 shows the serum levels of ADMA according to tertiles of serum carotenoid levels by sex. In women, serum ADMA levels were significantly decreased in the highest tertiles of serum α-carotene and β-carotene (P = 0.019, 0.035, respectively) compared to those in the lowest tertiles. There were no significant differences in serum ADMA levels between tertiles of serum carotenoid levels in men.

Table 3 shows the age-adjusted and multivariable-adjusted ORs and 95% CIs for elevated serum ADMA levels of serum carotenoids by sex. In women, the age-adjusted OR for elevated serum ADMA levels were significantly decreased in the highest tertiles of serum β-cryptoxanthin (OR 0.47, 95% CI 0.23–0.95), α-carotene (OR 0.39, 95% CI 0.18–0.79) and β-carotene (OR 0.36, 95% CI 0.17–0.73) compared to the lowest tertile. Significant and inverse associations of serum β-cryptoxanthin, α-carotene, and β-carotene with elevated serum ADMA for women did not vary after adjusting for potential confounders. There were no significant associations between serum levels of carotenoids and elevated serum ADMA in men. In men, however, significantly decreased ORs were observed in the highest tertiles of serum zeaxanthin/lutein (OR 0.23, 95% CI 0.06–0.69) and α-carotene (OR 0.26, 95% CI 0.07–0.82), and in the middle and highest tertiles of serum β-carotene (OR 0.27, 95% CI 0.09–0.74 and OR 0.20, 95% CI 0.03–0.88, respectively) compared to the lowest tertiles as with women, when the tertiles cutoff points of women were extrapolated to men (Table 4). We calculated ORs and 95% CIs for elevated serum ADMA levels using the tertile cutoff points of men or women after the exclusion of current smokers, because smoking, a potent source of oxidative stress, may have a large effect on the results. Exclusion of smokers did not change the results (data not shown).

DISCUSSION

In this study, we found that serum levels of carotenoids, such as α-carotene and β-carotene, were negatively associated with serum ADMA levels in women. In men, there were significant negative associations between serum ADMA levels and serum carotenoids such as zeaxanthin/lutein, α-carotene, and β-carotene, when we extrapolated the tertile cutoff points of women to men. These associations were invariant even after adjusting for major confounders, including age, smoking and drinking habits, BMI, eGFR, serum γ-GTP activities, hypertension, diabetes, and dyslipidemia. Recently, Goralczyk et al14 reported that plasma ADMA levels were negatively associated with vegetable consumption. Our findings among women are consistent with the suggestion that carotenoids may play a role in the mechanism underlying the negative association between circulating ADMA levels and vegetable consumption.

ADMA inhibits endogenous NOS and reduces NO production. ADMA is a risk factor for endothelial dysfunction, and an elevated circulating ADMA level is an independent risk factor for progression of CVD26 and arteriosclerosis.27 Therefore, the inhibition of circulating ADMA may protect against CVD.

Urinary excretion removes a small amount of circulating ADMA, but the bulk of ADMA is degraded by DDAH after uptake from the circulation.12,13 DDAH is a hydrolytic enzyme for the clearance of ADMA and plays an important role in adjusting ADMA levels. Decreased DDAH activity may be the main mechanism responsible for increased ADMA levels. DDAH activity is decreased by increased oxidative stress. Because DDAH has a sulphydryl group in its active catalytic site, DDAH is vulnerable to oxidative stress.28,29
### Table 1. Characteristics of study subjects

| Percentiles of ADMA | Men | Women | Sex differences |
|---------------------|-----|-------|-----------------|
|                     | ≤25th | 25th<, <75th | ≥75th | Total | ≤25th | 25th<, <75th | ≥75th | Total | P |
| n                   | 51   | 101   | 203            | 67   | 133  | 67   | 267 |
| Agea (years)        | 64.1 ± 9.9 | 67.8 ± 9.6 | 66.3 ± 10.7 | 66.5 ± 10.0 | 62.5 ± 10.4 | 67.0 ± 9.4d | 65.7 ± 8.9 | 65.6 ± 9.7 | 0.319d |
| ADMAb (µmol/L)      | 0.53 (0.50–0.56) | 0.70 (0.64–0.77) | 1.02 (0.90–1.05) | 0.72 (0.58–0.86) | 0.51 (0.48–0.55) | 0.64 (0.60–0.68) | 0.81 (0.75–0.86) | 0.64 (0.56–0.71) | <0.001d |
| Zeaxanthin/β-caroteneb (µmol/L) | 1.25 (0.93–1.77) | 1.21 (0.87–1.84) | 1.11 (0.87–1.47) | 1.19 (0.90–1.72) | 1.48 (1.23–2.06) | 1.48 (1.20–2.02) | 1.48 (1.23–2.01) | 1.46 (1.20–1.97) | <0.001d |
| Lycopeneb (µmol/L)  | 0.17 (0.10–0.24) | 0.19 (0.12–0.28) | 0.18 (0.12–0.26) | 0.18 (0.12–0.26) | 0.34 (0.25–0.47) | 0.31 (0.22–0.47) | 0.29 (0.20–0.39) | 0.31 (0.22–0.45) | <0.001d |
| α-Caroteneb (µmol/L) | 0.44 (0.25–0.82) | 0.51 (0.32–0.79) | 0.54 (0.35–0.82) | 0.50 (0.33–0.82) | 0.73 (0.52–1.09) | 0.68 (0.45–1.08) | 0.64 (0.40–1.14) | 0.71 (0.48–1.10) | <0.001d |
| BMIc (kg/m²)        | 21.3 ± 3.1 | 21.3 ± 3.1 | 21.0 ± 2.9 | 21.4 ± 3.0 | 23.4 ± 3.3 | 23.7 ± 3.6 | 23.4 ± 3.8 | 23.6 ± 3.6 | 0.141d |
| SBPd (mm Hg)        | 136.8 ± 19.7 | 131.0 ± 15.6 | 133.3 ± 15.8 | 133.0 ± 16.9 | 131.8 ± 15.2 | 135.0 ± 18.9 | 133.9 ± 16.4 | 133.9 ± 17.4 | 0.585d |
| HDL-cholesterold (mg/dL) | 82.8 ± 12.1 | 78.1 ± 10.2f | 78.6 ± 9.7 | 78.4 ± 10.7 | 78.7 ± 8.8 | 78.3 ± 9.0 | 78.5 ± 7.8 | 78.5 ± 8.6 | 0.288d |
| Triglyceridesd (mg/dL) | 24.1 ± 3.3 | 23.9 ± 3.0 | 24.2 ± 2.9 | 24.0 ± 3.0 | 23.4 ± 3.3 | 23.7 ± 3.6 | 23.4 ± 3.8 | 23.6 ± 3.6 | 0.141d |
| Total cholesterold (mg/dL) | 57.6 ± 12.0 | 56.8 ± 13.3 | 53.3 ± 12.3 | 55.8 ± 12.7 | 66.0 ± 14.0 | 64.4 ± 12.9 | 64.9 ± 14.5 | 64.9 ± 13.6 | <0.001d |
| LDL-cholesterold (mg/dL) | 121.9 ± 30.5 | 123.6 ± 28.7 | 120.4 ± 31.8 | 122.4 ± 29.8 | 126.5 ± 33.4 | 128.8 ± 31.3 | 130.3 ± 30.0 | 127.8 ± 31.4 | 0.098d |
| γ-GTPg (IU/L)       | 50.8 (27.0–94.0) | 37.0 (24.0–53.5)f | 35.8 (23.0–47.0)f | 39.7 (24.0–62.0) | 25.3 (14.0–29.3) | 24.1 (15.0–38.0) | 22.3 (14.0–39.0) | 23.9 (15.0–35.0) | <0.001d |
| eGFRh (ml/min/1.73m²) | 71.4 ± 13.7 | 69.0 ± 15.7 | 75.4 ± 16.6 | 71.2 ± 15.7 | 71.2 ± 13.6 | 71.4 ± 15.4 | 68.3 ± 13.1 | 70.6 ± 14.4 | 0.657 |
| Hypertensioni (%)   | 37 (72.6) | 55 (54.5) | 27 (52.9) | 119 (58.6) | 33 (40.3) | 87 (65.4) | 40 (59.7) | 160 (59.9) | 0.776* |
| Diabetesi (%)       | 8 (157) | 17 (16.8) | 5 (9.8) | 30 (14.8) | 7 (10.5) | 15 (11.4) | 5 (7.5) | 27 (10.2) | 0.129* |
| Dyslipidemii (%)     | 30 (58.8) | 48 (40.0) | 27 (52.9) | 105 (52.0) | 35 (52.2) | 64 (48.5) | 39 (58.2) | 138 (51.9) | 0.983* |
| SmOKing habitii (%) | 15 (29.4) | 26 (25.7) | 10 (19.6) | 51 (25.1) | 75 (85.1) | 110 (82.7) | 54 (80.6) | 221 (82.8) | <0.001a |
| Former               | 26 (51.0) | 59 (58.4) | 32 (62.8) | 117 (57.6) | 6 (9.0) | 13 (9.8) | 9 (13.4) | 28 (10.5) | 0.038 |
| Current              | 10 (19.6) | 16 (16.8) | 9 (17.7) | 35 (17.2) | 4 (6.0) | 10 (7.5) | 4 (6.0) | 18 (6.7) | 0.845 |
| Drinking habitii (%) | 10 (19.6) | 29 (28.7) | 22 (43.1) | 61 (30.1) | 51 (76.1) | 98 (73.7) | 46 (88.7) | 195 (73.0) | <0.001d |
| Never                | 1 (2.0) | 10 (9.9) | 1 (2.0) | 12 (5.9) | 1 (1.5) | 2 (1.5) | 2 (3.0) | 5 (1.9) | 0.193 |
| Former               | 40 (78.4) | 62 (61.4) | 28 (54.9) | 130 (64.0) | 15 (22.4) | 33 (28.4) | 19 (28.4) | 67 (25.1) | 0.571d |

Abbreviations: ADMA, asymmetric dimethylarginine; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; γ-GTP, γ-glutamyltranspeptidase.

*Data are expressed as mean values ± standard deviation.

*Data are expressed as geometric mean values and 25th–75th percentiles in parentheses.

*Data are expressed as number and percentages in parentheses.

*Chi-squared test (203 men vs 267 women).

P < 0.05 (vs lowest quartile, Tukey-Kramer HSD test).

P < 0.01 (vs lowest, Tukey-Kramer HSD test).

P < 0.001 (vs lowest quartile, Tukey-Kramer HSD test).

P < 0.001 (vs highest quartile, Tukey-Kramer HSD test).
Oxidative stress is caused by an imbalance between reactive oxygen species (ROS) generation and the antioxidant defense system. Increased oxidative stress also indicates enhanced production of ROS. Therefore, inhibition of oxidative stress by antioxidants may increase DDAH activity and prevent the increase of ADMA levels.

Carotenoids have antioxidant properties\(^{16}\) and anti-inflammatory effects.\(^{30}\) Serum carotenoid levels have been associated with increased ADMA levels.\(^{16}\) A possible mechanism is that increased oxidative stress by antioxidants may increase DDAH activity and prevent the increase of ADMA levels.
Women were extrapolated to men, signifying a common mechanism between serum ADMA levels and elevated serum ADMA in men in the present study. Some epidemiological studies have shown that higher intake of vegetables and fruits or higher circulating carotenoid levels are associated with decreased serum carotenoid levels by increased oxidative stress.34 The antioxidant properties and anti-inflammatory effects of carotenoids might explain the possible role of carotenoids in the prevention of CVD. This relationship may be one reason why increased vegetable consumption decreases CVD risk. However, it is uncertain whether circulating carotenoids increase the oxidative stress. Oxidative stress34 and may have had an impact on the sex difference of CVD.35,36 Since high doses of carotenoids could have a pro-oxidant effect, one possibility is that the protective effects of carotenoids against CVD disappear at the high doses used in supplementation studies. We were unable to assess the effect of supplementation with β-carotene in our study, because only one man and three women in this study used supplements. We do not necessarily recommend dietary supplements, such as β-carotene, as large randomized trials have found that β-carotene supplementation is not effective for preventing CVD.35,36 Since high doses of carotenoids could have a pro-oxidant effect, one possibility is that the protective effects of carotenoids against CVD disappear at the high doses used in supplementation studies. We were unable to assess the effect of supplementation with β-carotene in our study, because only one man and three women in this study used β-carotene supplements.

The present study has several limitations. First, this study was unable to examine issues of causality because of the cross-sectional design. We hypothesized that increased serum levels of carotenoids may protect against decreased DDAH activity caused by oxidative stress. However, it is possible that the negative associations between serum ADMA levels and serum carotenoid levels are due to oxidative stress that is generated in the arteriosclerosis process, including endothelial dysfunction. A prospective study is thus required to confirm our results and clarify true causal relationships. Second, the antioxidant properties of estrogen and the differences in muscle mass. Smoking and alcohol drinking, which were both more common among men in the present study, are associated with decreased serum carotenoid levels by increased oxidative stress and may have had an impact on the sex difference of oxidative stress.

Table 4. Odds ratios for elevated serum ADMA levels in men using the tertile cutoff points of women

| Percentiles of ADMA | Range (µmol/L) | n | ADMAa (µmol/l) | Age-adjusted Odds ratio (95%CI) | Multivariate adjusted Odds ratio (95%CI)b |
|---------------------|---------------|---|----------------|-------------------------------|------------------------------------------|
| Zeaxanthin/lytein   | Low 0.38–1.31 | 121 | 0.73 (0.59–0.89) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) |
|                     | Middle 1.34–1.82 | 41 | 0.74 (0.57–0.88) | 0.86 (0.37–1.86) | 0.81 (0.33–1.90) |
|                     | High 1.83–2.22 | 41 | 0.66 (0.57–0.74) | 0.25 (0.07–0.89) | 0.23 (0.06–0.69) |
| P for trend         |               |   |                | 0.084                          | 0.018                                    | 0.019                                    |
| β-Cryptoxanthin     | Low 0.03–0.25 | 142 | 0.71 (0.58–0.87) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) |
|                     | Middle 0.26–0.39 | 41 | 0.74 (0.62–0.87) | 1.10 (0.48–2.40) | 0.93 (0.38–2.15) |
|                     | High 0.41–2.23 | 20 | 0.70 (0.58–0.84) | 0.74 (0.20–2.18) | 0.72 (0.17–2.44) |
| P for trend         |               |   |                | 0.632                          | 0.755                                    | 0.835                                    |
| Lycopene            | Low 0.07–0.51 | 99 | 0.71 (0.58–0.83) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) |
|                     | Middle 0.53–0.96 | 71 | 0.73 (0.59–0.90) | 1.47 (0.73–2.95) | 1.66 (0.79–3.52) |
|                     | High 1.01–2.44 | 33 | 0.73 (0.59–0.87) | 1.12 (0.42–2.75) | 1.20 (0.43–3.15) |
| P for trend         |               |   |                | 0.327                          | 0.575                                    | 0.447                                    |
| α-Carotene          | Low 0.02–0.19 | 119 | 0.74 (0.59–0.89) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) |
|                     | Middle 0.20–0.35 | 54 | 0.68 (0.55–0.81) | 0.59 (0.26–1.25) | 0.56 (0.23–1.30) |
|                     | High 0.38–2.15 | 30 | 0.71 (0.62–0.80) | 0.35 (0.10–0.99) | 0.26 (0.07–0.82) |
| P for trend         |               |   |                | 0.131                          | 0.037                                    | 0.021                                    |
| β-Carotene          | Low 0.04–1.06 | 145 | 0.73 (0.58–0.89) | 1.00 (1.00–1.00) | 1.00 (1.00–1.00) |
|                     | Middle 1.08–1.79 | 39 | 0.68 (0.56–0.79) | 0.41 (0.15–1.02) | 0.27 (0.09–0.74) |
|                     | High 1.91–3.73 | 19 | 0.70 (0.64–0.81) | 0.27 (0.04–1.00) | 0.20 (0.03–0.88) |
| P for trend         |               |   |                | 0.268                          | 0.023                                    | 0.008                                    |

Abbreviations: ADMA, asymmetric dimethylarginine; 95%CI, confidence intervals; BMI, body mass index; eGFR, estimated glomerular filtration rate; γ-GTP, γ-glutamyltranspeptidase.

aElevated serum ADMA levels: greater than the 75th percentile of serum ADMA.
bData are expressed as geometric mean values and 25th–75th percentiles in parentheses.
cOdds ratios adjusted for age, smoking habits, drinking habits, BMI, eGFR, serum γ-GTP activities, hypertension, diabetes, and dyslipidemia.
statistical power of our analysis may not be high, especially for men, due to the small sample size. Lack of an association observed in analysis of men may mean that the sample size was not large enough to detect a weak association. Future larger studies are required to confirm our findings. Third, although confounding was appropriately adjusted for in our analysis, residual confounding cannot be completely ruled out.

In conclusion, higher serum carotenoid levels, such as α-carotene and β-carotene, were significantly and independently associated with decreased serum ADMA levels in a Japanese population. These findings suggest that maintaining a diet rich in vegetables and fruits could help prevent elevated ADMA levels, which are associated with the risks of arteriosclerosis and CVD.

ACKNOWLEDGEMENTS

This study was supported by Aichi Health Promotion Foundation. We thank the participants and staff of the Health Examination Program for Residents of Yakuino, Hokkaido, Japan.

Conflicts of interest: None declared.

REFERENCES

1. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489–509.
2. Hermann M, Flammer A, Lüscher TF. Nitric oxide in hypertension. J Clin Hypertens (Greenwich). 2006;8 Suppl 4:17–29.
3. Nava E, Noll G, Lüscher TF. Nitric oxide in cardiovascular diseases. Ann Med. 1995;27:343–51.
4. Chatterjee A, Black SM, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vasc Pharmacol. 2008;49:134–40.
5. Pitorco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA, Zuppi C, et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud. 2010;7:15–25.
6. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–5.
7. Kielstein JT, Bode-Böger SM, Frölich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation. 2003;107:1891–5.
8. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46:518–23.
9. Böger RH, Bode-Böger SM, Szuba A, Tsoa PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842–7.
10. Stühlinger MC, Abbasi F, Chu JW, Lamedola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420–6.
11. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152:493.e1–8.
12. Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005;10 Suppl 1:S73–81.
13. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455–9.
14. Goraleczk T, Tisonczyk J, Fijorek K, Undas A. High tea and vegetable consumption is associated with low ADMA generation in older healthy subjects. Metabolism. 2012;61:1171–6.
15. Krinsky NI. Carotenoids as antioxidants. Nutrition. 2001;17:815–7.
16. McCall MR, Frei B. Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med. 1999;26:1034–53.
17. Campbell DR, Gross MD, Martini MC, Grandits GA, Slavin JL, Potter JD. Plasma carotenoids as biomarkers of vegetable and fruit intake. Cancer Epidemiol Biomarkers Prev. 1994;3:493–500.
18. Gey KF, Stähelin HB, Eichholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and stroke: Basel Prospective Study. Clin Investig. 1993;71:3–6.
19. Morris DL, Kritchevsky SB, Davis CE. Serum carotenoids and coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. JAMA. 1994;272:1439–41.
20. Ito Y, Ochiai J, Sasaki R, Suzuki S, Kusuhara Y, Morimitsu Y, et al. Serum concentrations of carotenoids, retinol, and alphatocopherol in healthy persons determined by high-performance liquid chromatography. Clin Chim Acta. 1990;194:131–44.
21. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.
22. Nijveldt RJ, Teerlink T, Siroen MP, van Lamalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr. 2003;22:17–22.
23. Lee DH, Gross MD, Jacobs DR Jr. Cardiovascular Risk Development in Young Adults Study. Association of serum carotenoids and tocopherols with gamma-glutamyltransferase: the Cardiovascular Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2004;50:582–8.
24. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3–107.
25. Japan Atherosclerosis Society. Japan Atherosclerosis Society
(JAS) guidelines for prevention of atherosclerotic cardiovascular diseases. J Atheroscler Thromb. 2007;5:5–57.

26. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592–600.

27. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141–6.

28. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99:3092–5.

29. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987–92.

30. van Herpen-Broekmans WM, Klöpping-Ketelaars IA, Bots ML, Kuft C, Princen H, Hendriks HF, et al. Serum carotenoids and vitamins in relation to markers of endothelial function and inflammation. Eur J Epidemiol. 2004;19:915–21.

31. Bazzano LA, Serdula MK, Liu S. Dietary intake of fruits and vegetables and risk of cardiovascular disease. Curr Atheroscler Rep. 2003;5:492–9.

32. Ito Y, Kurata M, Suzuki K, Hamajima N, Hishida H, Aoki K. Cardiovascular disease mortality and serum carotenoid levels: a Japanese population-based follow-up study. J Epidemiol. 2006;16:154–60.

33. Bloomer RJ, Fisher-Wellman KH. Blood oxidative stress biomarkers: influence of sex, exercise training status, and dietary intake. Gend Med. 2008;5:218–28.

34. Aoki K, Ito Y, Sasaki R, Ohtani M, Hamajima N, Asano A. Smoking, alcohol drinking and serum carotenoids levels. Jpn J Cancer Res. 1987;78:1049–56.

35. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–9.

36. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150–5.